Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + fluorouracil + vitamin C + vitamin E

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination of three chemotherapeutic agents (cyclophosphamide, doxorubicin, and fluorouracil) commonly known as FAC or CAF regimen, with the addition of antioxidant vitamins C and E. The FAC component is a standard chemotherapy protocol used in the treatment of breast cancer. The addition of vitamins C and E is not a standard clinical practice, and research on the benefits of combining these antioxidants with chemotherapy is limited.

Targets

TOP2A (DNA topoisomerase II)DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + fluorouracil + vitamin C + vitamin E.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + fluorouracil + vitamin C + vitamin E.

Explore the full profile